Sarepta Therapeutics (SRPT) Gets a Buy From Piper Sandler

TipRanks50minutes ago · Ratings

J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating

Futu News04:31 · Ratings

Sarepta Therapeutics: Strong Elevidys Launch and Promising Pipeline Drive Buy Rating

TipRanks03:56 · Ratings

Sarepta Sees Prelim Yr-end 2024 Cash, Cash Equivalents, Restricted Cash and Investments Balance of About $1.5 B >SRPT

Dow Jones01:27

Sarepta Announces Q4 2024 Revenue Of $638.2M, Exceeding Guidance; ELEVIDYS Revenue At $384.2M; RNA PMO Revenue At $254M; FY24 Revenue Totals $1.79B; $1.5B In Cash And Investments At Year-End 2024; Reiterates 2025 Revenue Guidance Of $2.9B-$3.1B

Benzinga01:26

Sarepta Therapeutics Preliminary ELEVIDYS Net Pdt Rev Totaled $384.2 M in 4Q >SRPT

Dow Jones01:26